Stockreport

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results [Yahoo! Finance]

Kyverna Therapeutics, Inc.  (KYTX) 
PDF Aligned with the U.S. Food and Drug Administration (FDA) on a registrational Phase 2 trial design for ongoing KYSA-8 trial in stiff person syndrome; 70% of study enroll [Read more]